FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Veozah Liver Injury Warning

[ Price : $8.95]

FDA says it has added a Warning to labeling for Astellas Veozah about the risk of rare but serious liver injury.

Recommendations on Rare Disease Collaboration

[ Price : $8.95]

A new National Academies book on collaboration in rare disease drug development lists steps it recommends that FDA take.

GDUFA ANDA Amendment Submissions

[ Price : $8.95]

FDA publishes a guidance on submitting ANDA amendments under GDUFA 3.

Regulatory Review Period for Technegas

[ Price : $8.95]

Federal Register notice: FDA determines the regulatory review period for Cyclomedica Australias Technegas (technetium Tc 99m-label...

Regulatory Review Period for Ztalmy

[ Price : $8.95]

Federal Register notice: FDA determines the regulatory review period for Marinus Pharmaceuticals Ztalmy (ganaxolone), indicated fo...

OPDP Hits AbbVie Over Serena Williams DTC Ad

[ Price : $8.95]

CDERs Office of Prescription Drug Promotion cites AbbVie in a just-released untitled letter over its television direct-to-consumer...

3 FDA Innovative Manufacturing Action Steps

[ Price : $8.95]

FDA issues a strategy document on innovative manufacturing technologies with three action steps it will take.

FDA Warns 2 Chinese Labs About Data Concerns

[ Price : $8.95]

FDA says it sent Warning Letters to two Chinese nonclinical labs airing concerns about data integrity.

Lawsuit Against FDA Dismissed on Ripeness Grounds

[ Price : $8.95]

The Washington, DC District Court dismisses a Vanda Pharmaceuticals lawsuit against FDA that challenged the agencys bioequivalence...

Ocaliva Confirmatory Trial Fails: FDA

[ Price : $8.95]

FDA asks members of its Gastrointestinal Drugs Advisory Committee whether they believe that the benefits of using Intercepts Ocali...